• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

    2. HEALTH CARE
    3. Laferobionum 150,000 IU, 10 suppositories — Made in Ukraine — Free Delivery

    Laferobionum 150,000 IU, 10 suppositories — Made in Ukraine — Free Delivery


    Brand: Biopharma
    Product Code: Laferobionum
    Availability: In Stock
    $26.53
    Add to Cart

    Pharmacological properties

    Interferon alfa-2b recombinant has a pronounced antiviral, antiproliferative and immunomodulatory effect. the complex composition of laferobion determines a number of new effects: in combination with tocopherol acetate and ascorbic acid, the antiviral activity of recombinant interferon alpha-2b increases 10-14 times, its immunomodulatory effect on t- and b-lymphocytes is enhanced, the content of immunoglobulin is normalized e. antibodies are not formed , neutralizing the antiviral activity of recombinant interferon alfa-2b, even with the use of interferon for 2 years, the functioning of the endogenous system is normalized.

    Indications

    For children: in the complex therapy of acute respiratory viral infections (ARVI).

    Application

    For children: in the complex therapy of ARVI, the recommended doses are:
    for newborns and premature babies, the preparation is prescribed at 150,000 IU, 2 suppositories per day with a 12-hour interval. Treatment courses and breaks between courses - 5 days.
    For premature infants with a gestational age of less than 34 weeks, the preparation should be prescribed 150,000 IU 3 times a day (after 8 hours) rectally. The course is 5 days.
    Children aged 1 to 7 years - 500,000 IU 2 times a day.
    Children aged 7-14 years - 1,000,000 IU 2 times a day for 5 days.

    Contraindications

    Hypersensitivity to the components of the preparation; the patient has thyroid dysfunction; the presence of severe visceral disorders in patients with kaposi's sarcoma; severe cardiovascular disease; psoriasis; severe liver and / or kidney dysfunction; epilepsy and other diseases of the central nervous system (including functional); chronic hepatitis against the background of progressive or decompensated cirrhosis of the liver; chronic hepatitis in patients receiving or recently receiving immunosuppressive therapy (except for a short course of corticosteroid therapy); a history of autoimmune hepatitis or other autoimmune diseases. oppression of the myeloid germ of hematopoiesis.

    Side effects

    All side reactions associated with the use of laferobion, minor or moderate, usually disappear after the end of treatment.
    General disorders: with the introduction of Laferobion, flu-like symptoms are possible: chills, fever, fatigue, lethargy, as well as headache, pain in muscles, joints, increased sweating; rarely - vomiting, dizziness, hot flashes. The occurrence of hypersensitivity reactions to the preparation is possible.
    Violations of the hematopoietic system: with prolonged use, leukopenia, thrombocytopenia, anemia, nosebleeds are possible.
    Disorders from the gastrointestinal tract, liver: increased levels of ALT and AST, alkaline phosphatase, loss of appetite, impaired liver function.
    Endocrine Disorders: Disorders of the thyroid gland.
    Disturbances from the central and peripheral nervous system: with prolonged use, dizziness, sleep disturbance, confusion, anxiety and depression, hyperexcitability, drowsiness, ataxia, paresthesia are possible.
    Violations of the cardiovascular system: possible hypertension or arterial hypotension; rarely - tachycardia.
    Skin and subcutaneous tissue disorders: allergic reactions, including rash (including herpes), itching, flushing.
    Respiratory system disorders: cough.
    Others: changes at the injection site, visual impairment, impaired renal function, electrolyte imbalance.

    Special instructions

    Treatment with laferobion should be carried out under the supervision of a physician.
    With prolonged use of the preparation, a complete blood count, liver, kidney and thyroid function are monitored.
    Before starting and regularly during treatment, all patients are advised to carry out a detailed analysis of peripheral blood, with mandatory qualitative and quantitative examination of blood parameters, as well as a biochemical blood test, including determination of the content of electrolytes, calcium, liver enzymes and creatinine.
    In all patients receiving the preparation, it is recommended to carefully monitor the level of albumin in the blood plasma and prothrombin time.
    Prescribe the preparation with caution if you have a history of diseases such as diabetes mellitus with episodes of ketoacidosis and COPD, with blood clotting disorders (including pulmonary artery thrombophlebitis), with severe myelosuppression.
    When treating with the preparation, it is necessary to ensure adequate hydration of the body; in case of manifestations of fever, other causes of its occurrence should be excluded. It is recommended to use the preparation against the background of antihistamine and antipyretic therapy.
    The development of severe and moderate side effects requires dose adjustment, and in some cases, treatment cancellation.
    Discontinue use of the preparation in cases of: prolongation of blood coagulation time (in patients with chronic hepatitis), manifestations of pulmonary syndrome and X-ray detection of infiltration or dysfunction of the lungs, the appearance or increase in the severity of visual impairment, dysfunction of the thyroid gland (deviation from the normal level of TSH), decrease plasma albumin levels and a decrease in prothrombin time.
    With the development of an immediate hypersensitivity reaction (urticaria, angioedema, bronchospasm, anaphylaxis), the preparation should be discontinued immediately and appropriate measures should be taken.
    After the expiration date, the use of the preparation is unacceptable. The preparation is not subject to repeated quality control and extension of the expiration date after its expiration.
    Use during pregnancy and lactation. There are no data on the use of the preparation during pregnancy and lactation.
    Children. Applied in pediatric practice (see APPLICATION).
    The ability to influence the reaction rate when driving or working with other mechanisms. Some of the adverse effects from the central nervous system associated with the use of the preparation can affect the ability of patients to drive vehicles and work with potentially dangerous mechanisms.

    Interactions

    With caution, the preparation should be used simultaneously with opioid preparations, analgesics, hypnotics and sedatives (potentially causing myelosuppressive effect).
    With simultaneous use with preparations that are metabolized by oxidation (including with xanthine derivatives - aminophylline and theophylline), the possibility of Laferobion's influence on oxidative metabolic processes should be taken into account. The concentration of theophylline in blood plasma must be monitored and, if necessary, the dosage regimen must be adjusted.
    When using the preparation in combination with chemotherapeutic preparations (cytarabine, doxorubicin, teniposide, cyclophosphamide), the risk of developing life-threatening toxic effects (their severity and duration) increases.
    With simultaneous use with zidovudine, the risk of developing neutropenia increases.

    Overdose

    To date, no cases of overdose of the preparation laferobion have been described. however, as with an overdose of any preparation, symptomatic therapy with monitoring of the functions of vital organs and careful monitoring of the patient's condition is recommended.

    Storage conditions

    In the original packaging to protect from light at a temperature of 2-8 ° C.

    There are no reviews for this product.
    VEV Healthcare Store © 2017